NCT07883213
A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Prurigo Nodularis.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Proportion of subjects with ≥4-point improvement from baseline in the Worst Itch Numerical Rating Scale (WI-NRS) at week 16
Timeframe: Up to week 16
Secondary (6)
Proportion of subjects with Investigator's Global Assessment score of 0 or 1 for PN stage (IGA PN-S) at efficacy Visit
Proportion of subjects with Investigator's Global Assessment score of 0 or 1 for PN Activity (IGA PN-A) at efficacy Visit
Change from the baseline in the WI-NRS at each other Visit
Change from baseline in Dermatology Life Quality Index (DLQI) score at efficacy Visit
Change from baseline in Hospital Anxiety and Depression Scale (HADS) at week 16
Show 1 moreShow less
Safety parameters
Arms and interventions
cohort 1:AK139 regiment 1Experimental
cohort 2:AK139 regiment 2Experimental
placeboPlacebo comparator
Biologicals: AK139
Other: Placebo